Cefuroxime and Bacterial Meningitis Treatment

Introduction to Cefuroxime's Role

Cefuroxime, a second-generation cephalosporin, has been studied for treating bacterial meningitis, but third-generation cephalosporins are superior and preferred as first-line agents, as recommended by the Infectious Diseases Society of America 1
Clinical trials have found third-generation cephalosporins to be superior to cefuroxime for the treatment of childhood bacterial meningitis, with a strength of evidence supporting the use of third-generation cephalosporins as first-line therapy 1

Current guidelines from the Infectious Diseases Society of America recommend third-generation cephalosporins (ceftriaxone or cefotaxime) as first-line empiric therapy for suspected bacterial meningitis, with a high strength of evidence supporting this recommendation 2, 3
For adults with suspected bacterial meningitis, the recommended empiric treatment is ceftriaxone 2g IV every 12 hours or cefotaxime 2g IV every 6 hours, as suggested by the Infectious Diseases Society of America 3
For patients aged 60 years or older, ampicillin/amoxicillin should be added to cover Listeria monocytogenes, according to the guidelines from the Infectious Diseases Society of America 3

For pneumococcal meningitis, treatment should continue for 10 days if the patient is clinically stable (up to 14 days if taking longer to respond), as recommended by the Infectious Diseases Society of America 2, 4
For meningococcal meningitis, treatment can be discontinued after 5 days if the patient has clinically recovered, according to the guidelines from the Infectious Diseases Society of America 2, 4
If no pathogen has been found, antibiotics can be stopped after 10 days if the patient has clinically recovered, as suggested by the Infectious Diseases Society of America 2